Effective long-term treatment with incobotulinumtoxin (Xeomin ®) without neutralizing antibody induction: a monocentric, cross-sectional study

ConclusionsThe present study confirms the low antigenicity of incoBoNT/A, which has immediate consequences for patient management, and the use of higher doses and shorter durations of reinjection intervals in botulinum toxin therapy.

Source: Journal of Neurology - January 19, 2020 Category: Neurology Source Type: research